survey result indic strong launch underway
trikafta launch initi stage earli approv investor focu
whether drug take major cystic fibrosi cf market rather
fast end conduct survey pulmonologist
prescrib trikafta assess earli script trend treatment plan trikafta survey
first street suggest trikafta pois penetr market
quickli would provid upsid near-term project inde see
trikafta sale vs consensu ep vs
consensu major survey respond plan aggress prescrib trikafta
plan put elig patient drug within month
strong initi demand happen survey physician collect prescrib
trikafta patient first three week approv give us confid
above-consensu trikafta sale estim consensu
think vertex differenti growth profil cf launch momentum associ
cash flow invest internal/extern pipelin posit compani
continu upsid describ recent reinstat coverag reiter
buy rate increas po us list
us today call christian merlo md mph associ professor john
hopkin et discuss trikafta launch well slide survey data
capac reimburs minor headwind launch
manag cite treatment capac cf center possibl constraint
launch survey earli key opinion leader kol feedback suggest cf
patient gener abl access pulmonologist interestingli pick
patient group priorit earli access trikafta initi thought
het-min cf patient could get rapid access reimburs like
biggest access barrier expect on-going challeng respond
cite need prior author initi insur denial said
survey respond difficulti reimburs process fill rate
estim point launch anticip process becom
effici time seamless process evolv cours
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
vertex biopharmaceut compani focus
discoveri develop market new
therapi treatment cystic fibrosi
rate vertex buy differenti growth
profil compar peer compani potenti
upsid on-going trikafta launch
new po
updat rais earn forecast po
base npv analysi forecast sale approv product
kalydeco orkambi symdeko trikafta assumpt
unchang wacc line peer compani similar size risk
vari termin growth rate asset base characterist patent life
given assumpt estim valu kalydeco
orkambi symdeko
trikafta prior net cash pipelin
exhibit question mani total cystic fibrosi patient prescrib trikafta
exhibit question estim percentag trikafta prescript written fill reimburs
exhibit question patient subgroup trikafta prescript written
exhibit question would describ reimburs process trikafta
exhibit question priorit patient see come month
exhibit question percentag elig patient put trikafta next month month month
exhibit question recommend stabl orkambi symdeko patient switch trikafta
exhibit question open end thought trikafta reimburs clinic profil vertex commerci outreach
exhibit implic think peak cf sale could higher consensu inflect point could come earlier
exhibit implic model chang trend
exhibit implic main focu trikafta forecast reason
exhibit anticip share out-performance launch progress consensu catch
exhibit implic increas price object
price object vertex base npv analysi
forecast sale approv product kalydeco orkambi symdeko
trikafta assum wacc line peer compani
similar size risk vari termin growth rate asset base
characterist patent life given assumpt estim
valu kalydeco orkambi symdeko
trikafta net cash pipelin
risk price object payer pushback price difficulti secur
reimburs agreement particularli eu clinic trial failur new
competitor cystic fibrosi
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
